Isotechnika has a powerhouse franchise in voclosporin
March 30, 2010 by leonardzehr · Leave a Comment
Dr. Robert Foster still longs to make Isotechnika’s (TSX: ISA) lead drug, voclosporin, the standard of care in the field of preventing organ rejection in transplantation surgery. This may seem somewhat unusual, since voclosporin is currently being considered by regulators in North America and Europe to treat uveitis, a chronic inflammation of the eye that [...]
Listen to BioTuesdays 
